Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/02—Algae
  • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to a polysaccharide hot-water extract of Capsosiphon fulvescens and an anticancer drug comprising it as an active ingredient. More specifically, the present invention relates to the polysaccharide extract of Capsosiphon fulvescens, which is prepared by quick- freezing, drying and grinding Capsosiphon fulvescens of Ulvaceae in the family of green algae, soaking the solid content in water and extracting at 80 ° C, and then precipitating in alcohol, and an anticancer drug comprising it as an active ingredient
• Capsosiphon fulvescens In the past, people used to get rid of Capsosiphon fulvescens with hydrochloric acid because it often caused troubles in a breeding ground for seaweed.
• Capsosiphon fulvescens has been recently known to be rich in all kinds of minerals such as iron, potassium, iodine and the like and vitamin A and C, and effective not only for prevention and sedation of gastric ulcer or duodenal ulcer but also for treatment of crapulence, it is already well known among gourmets.
• Capsosiphon fulvescens can be obtained only in the winter season, is very sensitive to an environment such that its growth is deteriorated in presence of any kind of contaminants, and easily melts by even a little amount of hydrochloric acid, it is difficult to apply aquaculture techniques as in seaweed production. Therefore, there is a need to develop Capsosiphon fulvescens, despite its limited harvest time, as a safe food with its natural taste and effects, and to find a way to increase its applicability by acquiring a functional substance meeting the needs.
• an object of the invention is to provide an anticancer substance that can be used industrially and has a high economic efficiency.
• Another object of the present invention is to provide a composition of high applicability by developing Capsosiphon fulvescens, despite its limited harvest time, as a safe food with its natural taste and effects and by discovering a functional substance meeting the needs, and a pharmaceutical composition or a functional food using the same.
• a polysaccharide hot-water extract of Capsosiphon fulvescens which is prepared by: subjecting Capsosiphon fulvescens in a family of green algae to a quick- freezing process at a temperature of -70 to -80 °C, drying in freeze dryer, and grinding to obtain a solid content; heating the solid content at a temperature of 80 to 100 °C and filtering; and washing the hot filtrate with an alcohol of about twice the volume, precipitating more than 90% of the extract, and thereby obtaining the polysaccharide.
• the alcohol is preferably ethanol.
• Another aspect of the present invention provides an anticancer drug comprising the polysaccharide hot-water extract of Capsosiphon fulvescens as an active ingredient and an edible or pharmaceutically allowable substance, in which the polysaccharide hot- water extract of Capsosiphon fulvescens is prepared by: subjecting Capsosiphon fulvescens in a family of green algae to a quick- freezing process at a temperature of -70 to -80 " C, drying in freeze dryer, and grinding to obtain a solid content; heating the solid content at a temperature of 80 to 100 ° C and filtering; and washing the hot filtrate with an alcohol of about twice the volume, precipitating more than 90% of the extract, and thereby obtaining the polysaccharide.
• the anticancer drug comprising the polysaccharide extract of
• Capsosiphon fulvescens as its active ingredient demonstrates the anticancer activity when administered in vivo, by inhibiting specific growth of cancer cells growth of without harming the gastric adenocarcinoma cell and the colon cancer cell of a human.
• the polysaccharide hot-water extract of Capsosiphon fiilvescens of the invention is effective for extraction of polysaccharide component in Capsosiphon fulvescens, and may be usefully used as an active ingredient for an anticancer drug comprising the polysaccharide hot-water extract because it is innoxious for gastric cancer cells and colorectal cancer cells but is capable of inhibiting the growth of specific cancer cells.
• FIG. 2 shows the effects of the hot-water extract of Capsosiphon fulvescens on human colon cancer cells by different concentrations.
• Example 1 was analyzed. To this end, 2Og of Capsosiphon fulvescens was soaked in 20Og of water and reacted at 80 °C for 2, 3, and 4 hours, respectively. Following the same procedure described in the Example 1, ethanol of twice the volume was added to a residual filtrate to precipitate polysaccharide, and the rate of recovery of the polysaccharide was calculated. As shown in Table 2 below, in case of extracting polysaccharide in hot-water extract of Capsosiphon fulvescens, the two-hour heating process recovered about 35.8% of polysaccharide out of the total of 2Og, while the three-hour heating process recovered about
• An AGS human gastric adenocarcinoma cell, a HT-29 human colon cancer cell, and IEC-6 (normal large intestinal cell) provided from Korean Cell Line Bank (School of Medicine at Seoul National University) for the experiment were cultured in a laboratory.
• the AGS and the HT-29 cells were cultured in an RPMI 1640 medium containing 100 units/ m ⁇ penicillinOstreptomycin and 10% FBS, while the IEC-6 cell was cultured in a DMEM medium, each being in incubators (37 ° C, 5% CO 2 ).
• the cells being cultivated were supplied twice a week.
• the AGS human gastric adenocarcinoma cell and the HT-29 human colon cancer cell were uniformly distributed into 96-well plates to 5xlO 4 cells/well, and diluted with an RPMI 1640 medium containing 10% FBS to be cultured. After 24 hours, the cells were cultured again in a serum-free RPMI 1640 for 24 hours. Later, the polysaccharide in hot-water extract of Capsosiphon fulvescens prepared by the Example 3 was added at various concentrations to the cells and the cells were cultured for additional 24 hours. 24 hours later, the MTS/ PMS solution (CellTiter 96 AQueous Non-Radioactive Cell Proliferation
• FIG. 1 and FIG. 2 graphically illustrates MTT analysis results of inhibition of proliferation in the human gastric adenocarcinoma cell and the human colon cancer cell, each having been treated with the polysaccharide extract of Capsosiphon fulvescens.
• MTT is reduced by the enzyme-catalyzed reaction of oxido-reductase existing in the mitochondrial inner membrane of a living cell, and forms an insoluble, purple formazan. The formazan was then dissolved to measure a survival rate depending on its color development.
• the MTT analysis results on the gastric adenocarcinoma cell line AGS and the colon cancer cell line HT-29 compared with the control, about 40% of the gastric adenocarcinoma cell and about 45% of the colon cancer cell were inhibited in their cell proliferation, when the polysaccharide extract of Capsosiphon fulvescens was added at the concentration of 0.25%. At the same concentration, however, no inhibitory effect of cell proliferation was observed on the normal small intestinal cell IEC-6 which was used as the control of the cancer cells.
• the polysaccharide extract of Capsosiphon fulvescens demonstrates its anticancer activity through the inhibition of cell growth specifically for the gastric cancer and the colorectal cancer and concentration dependently.
• the polysaccharide extract of Capsosiphon fulvescens kills cancer cells without harming healthy, normal cells.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Alternative & Traditional Medicine (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Botany (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicines Containing Plant Substances (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37889046

Family Applications (1)

Country Status (3)

Cited By (2)

Families Citing this family (3)

Citations (3)

Family Cites Families (5)

• 2005
  • 2005-09-23 KR KR1020050088623A patent/KR100714221B1/ko not_active IP Right Cessation
• 2006
  • 2006-09-08 JP JP2008532159A patent/JP2009508941A/ja active Pending
  • 2006-09-08 WO PCT/KR2006/003589 patent/WO2007035030A1/en active Application Filing

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events